Mitsubishi Tanabe Plans Five Phase III China Drug Trials In Five Years
This article was originally published in PharmAsia News
Mitsubishi Tanabe Pharma plans five Phase III trials of its drugs in China over the next five years, using earlier data from trials.
You may also be interested in...
After its historic first emergency approval, analysts at Bernstein has upgraded predictions for Pfizer's COVID-19 vaccine in 2021 and beyond.
How UK and EU device regulations will differ in 2021, UK approved bodies and Northern Ireland's unfettered access to the UK market were key themes at the ABHI’s annual regulatory conference.
Regulatory pressure to fully approve the first COVID-19 vaccine in China is mounting as top officials tour an inspection agency and two leading manufacturers.